Nasdaq

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed ...

Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful ...
Drug Store News

FDA approves Mylan’s generic Restasis

The Food and Drug Administration has approved Mylan’s generic Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use vials (eye drops) to increase tear production in patients whose tear ...
Monthly Prescribing Reference

First Generic Version of Restasis Gets FDA Approval

Credit: Getty Images. Cyclosporine ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated ...
Nasdaq

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

These are single-use vials and should be discarded after each use.For questions about ordering, please call Upsher-Smith at 1-800-654-2299. About BoraFounded in 2007, Bora Pharmaceuticals ("Bora" or ...
Morningstar

UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)

MAPLE GROVE, Minn., May 20, 2026 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), today announced the recent ...